Madrigal Pharmaceuticals Stock News

The stock price of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) increased by over 14% pre-market today. This is why it happened.

CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, p

CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, pla

Madrigal Pharmaceuticals Inc (MDGL) shares closed 4.1% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 27.3% year-to-date, down 48.7% over the past 12 months, and up 312.0% over the past five years. This week, the Dow Jones Industrial Average fell 2.5%, and the S&P 500 fell 4.1%. Trading Activity Trading volume this week was 4.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 62.2% The company's stock price performance over the past 12 months lags the peer average by 53.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Back in November, Madrigal presented superb data for the open-label portion of its Phase 3 MAESTRO-NAFLD-1 trial. Next month, the company is poised to release additional data for the blinded segment o

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

The stock price of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) increased by 2.95% in the previous trading session. This is why it happened.

Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022 Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) shares, rose in value on Friday, 12/17/21, with the stock price up by 2.15% to the previous days close as strong demand from buyers drove the stock to $77.56. Actively observing the price movement in the last trading, the stock closed the session at $75.93, falling within a range of $75.79 Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) Stock Could Be An Option To Consider Read More »

Morgan Stanley lessened its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 64.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 93,677 shares of the biopharmaceutical companys stock after selling 169,221 shares during the quarter. Morgan Stanley owned about 0.56% []

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fa

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatt

JMP Securities restated their buy rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a report published on Wednesday, Price Targets.com reports. JMP Securities currently has a $219.00 price target on the biopharmaceutical companys stock. Several other brokerages have also commented on MDGL. Evercore ISI began coverage on Madrigal Pharmaceuticals in a research report on Sunday, []